3/11/2014 6:46:05 AM
Concordia Healthcare Corp. closes $67.6 million bought deal financing
TORONTO , March 11, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (CXR.TO), is pleased to announce that it has closed its previously announced short form prospectus offering, on a "bought deal" basis, of 5,750,000 common shares (the "Common Shares") of Concordia , which includes the exercise by the Underwriters (as defined below) of an over-allotment option of 15%, for aggregate gross proceeds of $67,562,500 (the "Offering"). The Offering was completed at a price per Common Share of $11.75 by a syndicate of underwriters co-led by GMP Securities L.P. and Canaccord Genuity Corp. and including Barclays Capital Canada Inc., Beacon Securities Limited and Cormark Securities Inc.
Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population. The company's legacy pharmaceutical business consists of an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States .
Concordia operates out of facilities in Oakville, Ontario , Lenexa, Kansas (near Kansas City, Missouri ), Bannockburn , (near Chicago ), Illinois and Bridgetown, Barbados .
SOURCE Concordia Healthcare Corp.
please visit www.concordiarx.com or contact:
Kristen Van Vogt
416-815-0700 x 244
416-815-0700 x 225
Help employers find you! Check out all the jobs and post your resume.
comments powered by